Lv6
1740 积分 2022-10-25 加入
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
2天前
已完结
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
17天前
已完结
Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy
17天前
已完结
Antibody-drug conjugates (ADCs): “Smart Missiles” targeting cancer therapy
17天前
已完结
The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review
17天前
已完结
Effect of Tyrosine Kinase Inhibitors on Wound Healing and Tissue Repair: Implications for Surgery in Cancer Patients
19天前
已完结
Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology
19天前
已完结
Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody–Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization
19天前
已完结
Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions
19天前
已完结
Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer
21天前
已完结
皖公网安备34019202002308
